Match!
Maxim Sorokin
I.M. Sechenov First Moscow State Medical University
39Publications
9H-index
215Citations
Publications 39
Newest
#1Nicolas BorisovH-Index: 8
#2Maxim SorokinH-Index: 9
Last.Anton BuzdinH-Index: 9
view all 4 authors...
2 CitationsSource
#2Maxim SorokinH-Index: 9
Last.Anton BuzdinH-Index: 9
view all 5 authors...
Source
#1Victor TkachevH-Index: 5
#2Maxim Sorokin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
Last.Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
view all 5 authors...
1 CitationsSource
#1Maria SuntsovaH-Index: 9
#2Nurshat Gaifullin (MSU: Moscow State University)H-Index: 8
Last.Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
view all 14 authors...
Comprehensive analysis of molecular pathology requires a collection of reference samples representing normal tissues from healthy donors. For the available limited collections of normal tissues from postmortal donors, there is a problem of data incompatibility, as different datasets generated using different experimental platforms often cannot be merged in a single panel. Here, we constructed and deposited the gene expression database of normal human tissues based on uniformly screened original ...
2 CitationsSource
#1Nicolas Borisov (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 8
#2Irina Shabalina (PetrSU: Petrozavodsk State University)H-Index: 5
Last.Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
view all 8 authors...
Background Harmonization techniques make different gene expression profiles and their sets compatible and ready for comparisons. Here we present a new bioinformatic tool termed Shambhala for harmonization of multiple human gene expression datasets obtained using different experimental methods and platforms of microarray hybridization and RNA sequencing.
5 CitationsSource
#1Daniil NikitinH-Index: 3
Last.Anton BuzdinH-Index: 26
view all 9 authors...
Background: Retroelements (REs) are mobile genetic elements comprising ~40% of human DNA. They can reshape expression patterns of nearby genes by providing various regulatory sequences. The proportion of regulatory sequences held by REs can serve a measure of regulatory evolution rate of the respective genes and molecular pathways. Methods: We calculated RE-linked enrichment scores for individual genes and molecular pathways based on ENCODE project epigenome data for enhancer-specific histone mo...
Source
#1Daniil NikitinH-Index: 3
#2Andrew GarazhaH-Index: 10
Last.Anton BuzdinH-Index: 26
view all 10 authors...
In the article ‘Retroelement—Linked Transcription Factor Binding Patterns Point to Quickly Developing Molecular Pathways in Human Evolution,’ a number of transcription factor binding sites (TFBS) mapped on all retroelement classes were incorrectly calculated as sum of TFBS numbers separately mapped on LINEs, SINEs and LTR retrotransposons/endogenous retroviruses (LR/ERVs) [...]
Source
#1Anton Buzdin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
#2Maxim Sorokin (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 9
Last.Alexey Moiseev (MSMU: I.M. Sechenov First Moscow State Medical University)H-Index: 1
view all 14 authors...
Abstract Molecular diagnostics is becoming one of the major drivers of personalized oncology. With hundreds of different approved anticancer drugs and regimens of their administration, selecting the proper treatment for a patient is at least nontrivial task. This is especially sound for the cases of recurrent and metastatic cancers where the standard lines of therapy failed. Recent trials demonstrated that mutation assays have a strong limitation in personalized selection of therapeutics, conseq...
Source
#1Ivana JovčevskaH-Index: 3
#2Alja ZottelH-Index: 2
Last.Radovan KomelH-Index: 29
view all 8 authors...
World Health Organization grade IV diffuse gliomas, known as glioblastomas, are the most common malignant brain tumors, and they show poor prognosis. Multimodal treatment of surgery followed by radiation and chemotherapy is not sufficient to increase patient survival, which is 12 to 18 months after diagnosis. Despite extensive research, patient life expectancy has not significantly improved over the last decade. Previously, we identified FREM2 and SPRY1 as genes with differential expression in g...
Source
#1Ella L. Kim (University of Mainz)H-Index: 7
#2Anton BuzdinH-Index: 26
Last.Alf GieseH-Index: 26
view all 10 authors...
e13533Background: This study developed molecular guided tools for individualized selection of chemotherapeutics for recurrent glioblastoma (rGB). A consortium involving clinical neurooncologists, m...
1 CitationsSource
1234